[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hallym University Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":103},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100629834","a-text-based-expressive-writing-program-for-adolescents-at-risk-of-suicide-100629834",false,"NCT07479823","A Text-Based Expressive Writing Program for Adolescents at Risk of Suicide","Effectiveness of a Text-Based Expressive Writing Intervention for Suicidal Adolescents and Young Adults: A Randomized Controlled Trial","WRITE-SAFE","Inclusion Criteria:\n\n* Adolescents or young adults aged 13 to 24 years.\n* Individuals with a history of suicidal ideation, suicide attempts, or non-suicidal self-injury.\n* Individuals currently receiving mental health services or who have been evaluated as having suicide risk within the past 6 months.\n* Ability to read and write in Korean.\n* For participants under 19 years of age, both participant assent and parental consent are required.\n\nExclusion Criteria:\n\n* Individuals requiring immediate psychiatric hospitalization.\n* Severe intellectual disability or neurodevelopmental disorder that prevents participation in writing activities.\n* Acute psychosis or manic episode that would interfere with participation in the study.\n* Participation in another suicide prevention clinical trial during the study period.","ALL","13 Years","24 Years",{"count":21,"type":22},160,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn if a structured expressive writing program can help reduce suicidal thoughts in adolescents and young adults who have experienced suicidal thoughts, suicide attempts, or self-harm. The study will include participants aged 13 to 24 years who are receiving mental health care or have recently been identified as being at risk for suicide.\n\nThe main questions the study aims to answer are:\n\n* Does a structured expressive writing program lower suicidal thoughts compared with usual care alone?\n* Does the program improve depression, impulsivity, and self-esteem?\n\nResearchers will compare participants who receive the expressive writing program together with treatment as usual to participants who receive treatment as usual alone.\n\nParticipants will:\n\n* Be randomly assigned to one of two groups: a writing program group or a usual care group\n* Complete questionnaires about mood, suicidal thoughts, and well-being at the start of the study, after 4 weeks, and after 8 weeks\n* If assigned to the writing program group, complete guided writing activities several times per week for 4 weeks. Each writing session will take about 15 to 20 minutes and will focus on understanding emotions, personal experiences, relationships, and meaning in difficult experiences.\n\nResearchers will study whether this writing program is a helpful and practical way to support young people who are experiencing suicidal thoughts or emotional distress.",[28,29,30,31],"Suicidal Ideation","Suicide Risk","Self-Injurious Behavior","Adolescent Mental Health",[33,34,35,36,37],"Expressive Writing","Suicide Prevention","Adolescent Suicide","Self-Harm","Youth Mental Health","NOT_YET_RECRUITING","2026-03-13",{"date":41,"type":42},"2026-03-18","ACTUAL",{"date":44,"type":22},"2026-04-01",{"date":46,"type":22},"2028-03",{"name":48,"class":49},"Hallym University Medical Center","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100473061","phase-1-tepotinib-plus-paclitaxel-in-met-amplified-or-met-exon-14-alterated-gastric-and-gej-carcinoma-100473061","NCT05439993","Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma","A Phase 1b\u002F2 Study of Tepotinib in Combination With Paclitaxel in Patients With MET Amplified or MET Exon 14 Alterated Advanced Gastric and Gastroesophageal Junction Carcinoma","Inclusion Criteria:\n\n1. Have the willingness to sign a written informed consent document prior to any study specific precedures\n2. Age ≥ 19 years of male and female\n3. At each phase of the trial, subjects who meet the following requirements in the appropriate phase will be enrolled.\n\n   A. Phase 1b: Subjects with a histologically confirmed metastatic solid tumor that have progressed after treatment with approved therapies or for which there is no standard effective therapy available.\n\n   B. Phase 2b: Subjects with histologically confirmed locally advanced or metastatic gastric and gastroesophageal carcinoma that have progressed after treatment with first-line fluoropyrimidine-based chemotherapy, with MET amplified (copy number gain ≥3) or MET exon 14 skipping mutation in the archival or fresh tumor tissue specimen identified in study customized targeted DNA deep sequencing (NGS by gastric cancer panel). If the subject received adjuvant chemotherapy after curative gastric resection and lymph node dissection, adjuvant chemotherapy is considered to be the first-line palliative chemotherapy if the disease recurred during adjuvant chemotherapy or within 6 months after the completion of adjuvant chemotherapy.\n4. Patients must have measurable disease based on RECIST 1.1 (Phase 2 part only) Measurable disease will not be required for enrollment in the phase1b part. Patients with evaluable lesion only (without measurable lesion) can be enrolled in the phase 1b part.\n5. ECOG performance status 0-1\n6. Patients must have adequate organ and marrow function as defined below:\n\nExclusion Criteria:\n\n1. Active central nervous system (CNS) lesions (ie, those with radiologically unstable or symptomatic brain lesions). For those who receive radiation or surgical treatment, the subject can be enrolled if the subject is maintained without evidence of CNS disease progression for more than 4 weeks. However, patients with a leptomeningeal metastasis are excluded.\n2. Treatment with any of the following:\n\n   * Nitrosourea or mitomycin C within 6 weeks of the first dose of study treatment\n   * Any cytotoxic chemotherapy from a previous treatment regimen within 14 days. If the subject received an investigational drug from another clinical trial, the subejct can be enrolled after 2 weeks of last administration and more than 5 x half-life of the investigational drug. If monoclonal antibody therapy was given, the subject can be enrolled after four weeks after the last does.\n   * Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study treatment. If acute symptoms of radiation have fully resolved, the extent and timing of radiotherapy for eligibility can be discussed between the local investigator and principal investigator.\n   * Any previous exposure to a c-MET inhibitor\n3. History of allogeneic bone marrow transplantation or organ transplantation\n4. History of another primary cancer (excluding gastric cancer):\n5. Clinically significant cardiovascular disease including but not limited to:\n\n   * Acute coronary syndome within the 6 months prior to the initiation of study drug (including myocardial infarction or unstable angina, Coronary Artery Bypass Graft surgery, percuatneous coronary intervention and stenting)\n   * Current heart failure or past history of heart failure\n   * Left ventricle ejection fraction (LVEF) \\\u003C 50%; if there is no past history of heart failure, screening with echocardiography to confirm EF is not required.\n   * Current or past history of clinically significant cardiac arrhythmia (eg, complete left bundle branch block, third degree heart block)\n   * Any risk factors that prolong QTc or increase the probability of arrhythmia, including medication (eg: heart failure, hypokalemia, congenital long QT syndrome, history of Torsades de Pointes)\n6. Persistent uncontrolled hypertension as defined by: systolic \\>180 mmHg or diastolic \\>100 mmHg despite medical treatment\n7. Seropositivity of HIV or known active hepatitis B and\u002For active hepatitis C infection. Hepatitis B carriers may be enrolled if prophylactic use of an antiviral agent with minimal interaction with CYP3A4 is administered to inhibit HBV activation (eg. Entecavir, adefovir)\n8. Impairment of gastrointestinal function or gastrointestinal disorders (eg. untreated ulcerative disorders; uncontrolled nausea, vomiting, or diarrhea; absorption disorder syndrome; small bowel resection; ileostomy). Patients with ileostomcy will not allowed to be enrolled, but patients with colostomy can be enrolled to this study.\n9. As judged by the Investigator, all other symptoms and associated disease for which the investigator determined that participation in this study is contraindicated (e.g. Infection\u002Finflammation; severe liver dysfunction; bilateral diffuse interstitial lung disease; uncontrolled renal disease; unstable heart and lung disease; hemorrhagic disease; intestinal obstruction; unable to swallow oral pills; social and psychological problems, etc)\n10. Pregnant or lactating women. Pregnancy is defined as the state from conception confirmed by HCG clinical laboratory test to termination of pregnancy.\n11. Medical, psychiatric, cognitive, or other conditions that may interfere with the ability of the subject to understand the subject information, provide the informed consent, follow the protocol process, or complete the clinical trial\n12. Hypersensitivity to paclitaxel",{"count":58,"type":22},42,[60,61],"PHASE1","PHASE2","Purpose of this study is to define the maximal tolerated dose (MTD) and recommended phase 2 dose (RP2D) of paclitaxel and tepotinib combination therapy in patients with advanced tumors and to evaluate the efficacy of paclitaxel and tepotinib combination treatment as second-line therapy in patients with advanced gastric and gastroesophageal junction carcinomas (AGC\u002FGEJCs) with MET amplification or MET exon 14 alterations. This study is devided into Phase 1b and Phase 2 study.",[64,65],"Gastric Cancer","Gastroesophageal-junction Cancer","RECRUITING","2022-06-29",{"date":69,"type":42},"2022-07-05",{"date":71,"type":42},"2022-03-01",{"date":73,"type":22},"2026-06-30",{"name":48,"class":49},1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":75},"100422939","phase-3-optimal-duration-of-oxaliplatin-in-adjuvant-xelox-for-gastric-cancer-patients-exodox-100422939","NCT04787354","Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)","A Randomized Phase 3 Clinical Trial Investigating Optimal Duration of Oxaliplatin Administration in Postoperative XELOX (Oxaliplatin + Capecitabine) Adjuvant Chemotherapy for the Patients With Stage II\u002FIII Gastric Cancer","Inclusion Criteria:\n\n* Histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma patients who underwent curative surgery (D1 beta or D2 resection)\n* Pathologically confirmed stage II, III patients (AJCC 8th edition)\n* Age 19 years and older\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 2\n* Adequate marrow function (ANC \\> 1,500\u002FuL, Platelet \\>100,000\u002FuL, Hb \\> 8.0 g\u002FdL, patients with chronic anemia who require intermittent blood transfusions can also participate in the study)\n* Adequate renal function, with serum creatinine \\\u003C 1.5 x upper limit of normal (ULN).\n* Adequate hepatic function with serum total bilirubin ≤ 1.5 x ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN\n* Written, informed consent to the study\n\nExclusion Criteria:\n\n* Female patients who are pregnant or breast-feeding\n* Positive pregnancy test at baseline (postmenopausal women should be amenorrhea for at least 12 months to be considered non-fertile)\n* Sexually active men and women who are not willing to implement contraception during study and until 3 months after discontinuation of study drug\n* Evidence of metastasis (including cytologically confirmed malignant ascites)\n* Prior systemic chemotherapy or radiation therapy for stomach cancer\n* Patients who have not recovered from serious complications of gastrectomy\n* History of other malignancies within the last 3 years (excluding adequately treated basal cell carcinoma of the skin, in situ cancer of the cervix, non-metastatic thyroid cancer)\n* A history of clinically significant uncontrolled seizures, central nervous system disorders, or mental disorders, which make it impossible to understand the informed consent or interfere with compliance with oral drug intake\n* Clinically significant (i.e., active) heart disease: e.g. unstable angina requiring medication, symptomatic coronary artery disease, congestive heart failure with NYHA grade II or higher, severe cardiac arrhythmias or acute coronary syndrome in the past 6 months (including myocardial infarction)\n* Lack of integrity or malabsorption syndrome in the upper gastrointestinal tract, which is likely to affect the absorption of study drug\n* Serious uncontrolled infection or other serious uncontrolled disease\n* History of allograft requiring immunosuppression therapy\n* Received any investigational drug or procedure within 4 weeks prior to randomization\n* Active viral infection (for hepatitis B carrier, patients can be registered if HBV-DNA titer is less than 20,000 IU\u002FmL, and are allowed to use prophylactic antiviral agents by investigator's choice)\n* Active HIV infection\n* Patients with peripheral sensory neuropathy with functional impairment","19 Years",{"count":85,"type":22},976,[87],"PHASE3","This study aims to compare the efficacy and safety of reduced adjuvant XELOX treatment (4 cycles of XELOX followed by 4 cycles of capecitabine alone) to standard adjuvant XELOX treatment (8 cycles of XELOX).",[64],[91,92,93,94],"Stomach Neoplasms","Chemotherapy, Adjuvant","Oxaliplatin","Capecitabine","2022-02-04",{"date":97,"type":42},"2022-02-21",{"date":99,"type":42},"2021-11-01",{"date":101,"type":22},"2027-12-31",{"name":48,"class":49},""]